Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Releases Findings from TTR Amyloidosis Study

Premium

Alnylam Pharmaceuticals this week released data from a natural history study designed to measure blood levels of the wild-type and mutant versions of the gene transthyretin in both transthyretin-mediated amyloidosis patients and mutation carriers.

Alnylam is currently conducting a phase I study of an RNAi-based treatment for TTR amyloidosis, a hereditary, systemic disease caused by a mutation in the transthyretin gene (GSN 7/8/2010).

“Although it is known that serum TTR concentrations in [TTR amyloidosis] patients and gene carriers are below the normal range, little is known about temporal changes in TTR levels in either patients or carriers,” the company said. “Accordingly, Alnylam conducted a natural history study to measure serial TTR levels over a four week period in ATTR patients and gene carriers, and to determine the intra- and inter-patient variability in serum TTR.”

The study enrolled 26 patients and carriers of seven different amyloidogenic TTR mutations.

Data from this study showed that TTR levels were stable over time in patients and carriers. “The average serum TTR concentration was approximately 200 micrograms/mL with 10 to 20 percent intra-subject variability over the 28-day observation period,” Alnylam noted. “Results showed that inter-subject TTR variability was approximately 25 percent.”

Alnylam expects to report phase I data on its drug, ALN-TTR, in the third quarter.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.